|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on July 12, 2002; DOI 10.1182/blood-2002-02-0567.
NEOPLASIA
From the Division of Pediatric Hematology/Oncology,
Department of Pediatrics, University of California San Diego;
Department of Immunology, The Scripps Research Institute, La Jolla, CA;
Felsenstein Medical Research Center, Sackler School of Medicine, Tel
Aviv University, Beilinson Campus, Petach Tikva, Israel; and the
Chemistry Department, Bar Ilan University, Ramat Gan, Israel.
The novel prodrug of butyric acid, pivaloyloxymethyl butyrate
(AN-9), a histone deacetylase inhibitor, shows great promise as an
effective and relatively nontoxic anticancer agent for solid malignancies. However, little is known about its effects on
hematopoietic malignancies. In this study, we show that 21 primary
samples of acute leukemia were sensitive to the antiproliferative
effects of AN-9, with a 50% inhibitory concentration
(IC50) of 45.8 ± 4.1 µM. In colony-forming assays,
primary T-cell acute lymphoblastic leukemia (T-ALL) cells were 3-fold
more sensitive to AN-9 than the normal hematopoietic progenitors,
erythroid burst-forming units and granulocyte/monocyte
colony-forming units. AN-9 induced apoptosis in the T-ALL cell
line CEM. A common problem with cancer is chemoresistance, which is
often typical of relapsed cancers. Remarkably, a T-ALL sample at
diagnosis and an acute myeloid leukemia sample at relapse that were
resistant to doxorubicin in vitro were sensitive to AN-9, with
an IC50 of 50 µM for both samples. More strikingly,
samples from 2 infants with t(4;11) ALL obtained at diagnosis and
relapse each were the most sensitive to AN-9, with IC50
values of 25 µM and 17 µM, respectively. Furthermore, a
doxorubicin-resistant clone of HL60, HL60/ADR, obtained by the transfection of the MDR-1 gene, was equally
sensitive to AN-9 cytotoxicity as the parental cells. AN-9 induced the
expression of p21 in an infant leukemia sample with 11q23
rearrangement, but not in T- or B-precursor ALL. Collectively, our
results suggest that AN-9 is a selective agent for hematopoietic
malignancies that can circumvent the mechanisms of chemoresistance
limiting most conventional chemotherapy.
(Blood. 2002;100:3319-3324) The leukemias account for the largest number of
cases of childhood cancer. Acute lymphoblastic leukemia (ALL)
represents approximately three fourths, whereas acute myeloid leukemia
(AML) represents one sixth of the cases. Despite recent advances in the
treatment of childhood cancers, leukemias remain the primary cause of
cancer-related mortality among children in the United States. Although
ALL and AML are potentially curable diseases, with a 5-year survival of 70% for ALL and 40% for AML, once leukemia recurs, the outcome is
dismal. Therefore, there is a need for novel antileukemia agents, especially those that are effective for relapsed leukemias resistant to
existing chemotherapeutic agents.
Histone acetylation plays a key role in the regulation of transcription
by modulating chromatin structure.1-3 In general, histone
acetylation is associated with activation of transcription, whereas
histone deacetylation is associated with repression of transcription.
It has recently been established that many malignancies, particularly
leukemias, are associated with aberrant recruitment of histone
deacetylases (HDACs) or with mutations in histone acetyl transferases
such as EP300.4-6 For example, several investigators reported that the oncoprotein promyelocytic leukemia/retinoic acid
receptor- Pivaloyloxymethyl butyrate (AN-9), a butyric acid prodrug, is a
relatively new member of an established family of acyloxyalkyl ester
prodrugs of carboxylic acids that undergo rapid hydrolysis. Upon
hydrolysis, the resulting products are butyric acid, pivalic acids, and
formaldehyde (Figure 1). The anticancer
effect of AN-9 is assumed to stem primarily from the release of butyric
acid, an HDAC inhibitor.13 It is important to note,
however, that AN-9 is 10-fold more potent than butyric acid in vitro
and has anticancer effects in vivo not observed with butyric acid even at 10-fold higher concentrations.14 The increased potency
of AN-9 over butyric acid is most likely due to its increased
permeability across cell membranes, allowing for efficient delivery of
butyric acid to subcellular targets.15 AN-9 inhibits cell
proliferation and soft agar colony formation of a variety of cancer
cell lines and primary human solid tumor cells, including those of
colon, breast, ovary, lung, kidney, and bladder.13,16,17
In addition to being an antiproliferative agent, AN-9 has been shown to
induce differentiation and apoptosis in HL60
cells.18 Earlier studies in mouse tumor models
have demonstrated that AN-9 is an effective antitumor agent and
displays low toxicity.19 Currently, AN-9 is being studied
in a phase II clinical trial for non-small cell lung cancer. To date,
all in vitro and in vivo studies of AN-9 have been confined to solid
tumors, with the exception of a murine monocytic leukemia and the HL60
cell line. In this study, we investigated the in vitro therapeutic
efficacy of AN-9 in primary human acute leukemias, including
doxorubicin-resistant and/or clinically refractory acute leukemias. Our
findings demonstrate the selective toxicity of AN-9 to acute leukemias,
including drug-resistant relapsed leukemias, and thus provide the
rationale for the initiation of clinical trials of AN-9 in relapsed
acute leukemias.
Antibodies and reagents
Cell lines
Patient population and isolation of primary leukemia cells Heparinized bone marrow or peripheral blood samples were obtained at diagnosis and relapse from patients with AML or B-precursor ALL at the University of California in San Diego. T-ALL samples were obtained from patients enrolled in Pediatric Oncology Group protocols 9900 (ALL Biology Study) and 9673 (Relapsed T-ALL Study) and were shipped overnight to the University of California San Diego for biology studies. Bone marrow cells obtained from patients in complete remission who underwent diagnostic bone marrow examination were used as normal controls. Only excess samples obtained for clinical purposes were analyzed. These samples were collected under a protocol approved by the Institutional Review Board. Mononuclear cells were isolated by density gradient centrifugation through Ficoll-Hypaque (specific gravity 1.077 g/mL) at 400g for 30 minutes, followed by 2 washes in RPMI 1640 (Ammersham Biosciences, Uppsala, Sweden). The content of lymphoblasts, as determined by Wright stain, was generally 80% or higher. Leukemia cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 2 mM glutamine, and 1% penicillin/streptomycin (complete medium).3H-thymidine incorporation assay Primary leukemia and normal bone marrow cells were plated in complete RPMI at 75 × 103 cells per well in a 96-well plate. Leukemia and neuroblastoma cell lines were plated at 10 and 5 × 103 cells per well, respectively. Cells were treated with increasing concentrations of AN-9 or with 0.1% dimethyl sulfoxide (DMSO; control) for 3 days. Cells were then pulsed with 3H-thymidine at 1.6 µCi/well (0.0592 MBq) for 6 hours. Incorporation of 3H-thymidine was determined in a scintillation counter (Beckman Coulter, Fullerton, CA) after the cells were washed and deposited onto glass microfiber filters using cell harvester M-24 (Brandel, Gaithersburg, MD).Colony-formation assays Primary T-ALL and normal bone marrow cells were plated at 5 × 105 per 35-mm dish in methylcellulose medium with increasing concentrations of AN-9 for 14 days. An erythroid burst-forming unit (BFU-E) was identified as a large aggregate of more than 64 hemoglobinized cells or as clusters of 3 or more subcolonies consisting of 8 or more hemoglobinized cells per subcolony. The granulocyte/monocyte colony-forming unit (CFU-GM) was enumerated as a group of more than 50 granulocytic/monocytic translucent cells. T-ALL colonies were identified as clusters of more than 50 cells.Cytotoxicity assays Primary leukemia and CEM cells were plated in complete RPMI at 75 × 103 cells per well and 10 × 103 cells per well (96-well plate), respectively. Cells were treated with increasing concentrations of AN-9 or 0.1% DMSO for 3 days. The number of viable cells was determined by trypan blue exclusion.Apoptosis assays CEM cells were plated at 1.2 × 106 cells per well (6-well plate) in complete RPMI and treated with 0.1% DMSO or 60 and 75 µM AN-9 for 20 and 45 hours. Cells were then visualized and photographed using a Nikon Eclipse TE-300 inverted microscope and the SPOT camera (SPOT Diagnostic Instruments, Sterling Heights, MI). Alternatively, cells were stained with Alexa Fluor 488 annexin V and propidium iodide using the Vybrant Apoptosis Assay Kit (Molecular Probes, Eugene, OR) and then analyzed by flow cytometry using a FACScan flow cytometer and CellQuest 3.2.1 software (Becton Dickinson).Western blot analysis Primary leukemia cells (10-20 × 106) were treated with 10, 25, 50, and 100 µM AN-9 for 24 and 48 hours. As a control, cells were treated with 0.1% DMSO. Protein was extracted with 30 µL sodium dodecyl sulfate (SDS) lysis buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol, 5 mM dithiothreitol). Samples were heated in boiling water for 10 minutes, and then the lysate was passed through a 28-gauge needle to shear chromosomal DNA. Supernatants were then collected after spinning in a microfuge at 13 000 rpm for 10 minutes at 4°C. Proteins were resolved on an 8% SDS-polyacrylamide gel and transferred to Immobilon-P nylon membranes (Millipore, Bedford, MA). Membranes were probed with p21 and p27 antibodies at 0.5 µg/mL. Membranes were also probed with a -actin
antibody at 2 µg/mL as a control for protein loading. Antibody-bound
proteins were detected by chemifluorescence and analyzed using the
Storm 840 Phosphorimager (Molecular Dynamics).
Primary ALL cells are more sensitive than normal bone marrow cells to AN-9 The effect of AN-9 on DNA synthesis in both primary ALL and normal bone marrow was examined by 3H-thymidine incorporation assays. The results demonstrated that ALL cells were more sensitive than normal bone marrow cells to inhibition of 3H-thymidine uptake by AN-9 (Figure 2).
The mean 50% inhibitory concentration (IC50) of AN-9
in 6 normal bone marrow cell samples was 87 ± 5 µM. In contrast,
the mean AN-9 IC50 in 15 primary T-ALL samples was
50 ± 5 µM, and that in 2 B-precursor ALL samples was 44 µM and
54 µM (data not shown). The finding that both T- and B-cell ALL have
similar sensitivity to AN-9 suggests that the effects of AN-9 are not
lineage specific. Remarkably, however, primary leukemias obtained from
2 infants with an 11q23 rearrangement were the most sensitive to AN-9.
One of these samples was obtained from a patient who suffered from leukemia relapse shortly after bone marrow transplantation and became
refractory to reinduction chemotherapy. On 2 separate occasions during
his relapse, the IC50 of AN-9 was only 17 µM (Figure 2) and 13 µM (data not shown), respectively. The second infant ALL sample, collected at the time of diagnosis, had an AN-9
IC50 of 25 µM (Figure 2). To confirm the results obtained
by 3H-thymidine incorporation on the selectivity of AN-9
for leukemia, we performed colony-formation assays using normal bone
marrow cells and primary T-ALL cells. The mean IC50 of AN-9
in 6 primary T-ALL samples was 46.6 ± 1.1 µM, and those of 5 normal hematopoietic progenitors of BFU-E and CFU-GM were
159.7 ± 2.7 µM and 159.5 ± 2.9 µM, respectively (Figure
3). The difference in the AN-9 IC50 between T-ALL and normal hematopoietic progenitors was
highly significant, with P < .001. Thus, the results of
colony-formation assays confirm the selectivity of AN-9 for ALL rather
than normal bone marrow cells.
AN-9 is cytotoxic to ALL To distinguish between cytostatic and cytotoxic effects of AN-9, we performed cell-viability assays using both a T-ALL cell line, CEM, as well as primary T-ALL cells. The results of trypan blue exclusion assays demonstrated that AN-9 was cytotoxic to CEM and primary T-ALL in a dose-dependent manner (Figure 4).
The IC50 of AN-9 was 47 µM in CEM and 41 µM in primary T-ALL after 3 and 5 days of AN-9 treatment, respectively (Figure 4). At 75 µM AN-9, cytotoxic effects on CEM were evident as early as after 24 hours of incubation (data not shown). Induction of apoptosis by AN-9 To determine whether cytotoxicity of AN-9 involved the induction of apoptosis, we treated CEM cells with 0.1% DMSO (negative control), 60 or 75 µM AN-9, or with 5% ethanol (positive control) for 20 and 45 hours, and then examined them by flow cytometry after staining with Alexa Fluor 488 annexin V and propidium iodide. As shown in Figure 5, AN-9 induced apoptosis in CEM cells in a dose-dependent manner. For instance, treatment with 60 µM and 75 µM AN-9 for 45 hours resulted in 3.5% and 8.3% apoptotic cells, respectively. Percentage apoptosis in negative control cells was 0.5%, and that in the positive control cells was 10%. Late-stage apoptosis or necrosis was also evident after treatment with 60 and 75 µM AN-9 (data not shown).
To further confirm the results presented in Figure 5, CEM cells treated
with 75 µM AN-9 for 20 hours were photographed in a 12-well plate in
the absence of cell manipulations to avoid the loss of fragile
apoptotic cells. Results of a representative experiment as presented in
Figure 6B revealed numerous cells with fragmented nuclei as well as clusters of membrane-bound bodies (see
arrows), which are characteristic of apoptosis.
These findings demonstrate that apoptosis occurs within 20 hours and appears to be more extensive than the flow cytometry results indicate because no apoptosis was evident by flow cytometry at 20 hours (data not shown). This result is most likely due to the loss of apoptotic cells during the staining procedure before flow cytometry. AN-9 induces p21 in infant ALL, but not in T-ALL or B-precursor ALL Previous studies have reported the induction of p21 by butyrate and its correlation with cell-cycle arrest and apoptosis.23,24 To determine whether p21 is involved in AN-9 action, we examined the expression of p21 in response to AN-9 by Western blot analysis. As shown in Figure 7A, p21 was induced in a primary infant ALL sample within 24 hours of AN-9 treatment, and the levels declined by 48 hours, indicating a transient induction. In contrast, as presented in a representative experiment (Figure 7), induction of p21 by AN-9 was not observed in any of the 2 B-precursor ALL (Figure 7B) or the 4 primary T-ALL (Figure 7C, data shown for one patient) cells examined, even at AN-9 concentrations that effectively arrest DNA synthesis in ALL (Figure 2). The effects of AN-9 on the levels of p27, a homolog of p21, were also examined. The levels of p27 were not induced by AN-9 in B-precursor ALL or T-ALL (data not shown). These results suggest that the effects of AN-9 on T-ALL are independent of p21 or p27.
Drug-resistant primary leukemia and cancer cell lines are sensitive to AN-9 The finding that clinically refractory infant ALL cells are sensitive to AN-9 prompted us to determine whether AN-9 is cytotoxic to other drug-resistant malignant cells. The effect of AN-9 was examined in a doxorubicin-resistant clone of the myeloid leukemia cell line HL60, HL60/ADR, obtained by the transfection of the MDR-1 gene; and a doxorubicin-resistant neuroblastoma cell line, Be2c/ADR, induced by repeated exposure of Be2c to doxorubicin. The doxorubicin-sensitive (IC50 = 0.002 µM) and doxorubicin-resistant HL60 cells (IC50 > 2.0 µM) were equally sensitive to AN-9, with IC50 values of 52.0 ± 5.6 µM and 57.3 ± 10.7 µM, respectively (Table 1).
Similarly, the doxorubicin-sensitive (IC50 = 0.007 µM) and -resistant neuroblastoma cell lines (IC50 > 2.0 µM) were equally sensitive to AN-9, with IC50 values of 69.4 ± 8.4 µM and 70.7 ± 6.2 µM, respectively (Table 1). More important, a doxorubicin-resistant primary T-ALL and a relapsed AML that was refractory to chemotherapy were sensitive to the cytotoxicity of AN-9, each with an IC50 of 50 µM (Table 1), an IC50 similar to that obtained in doxorubicin-sensitive primary ALL (Figure 2). Taken together, these findings, in addition to the finding of heightened sensitivity to AN-9 of relapsed infant leukemia (Figure 2), suggest that AN-9 may be a promising agent for acute leukemias, even in cases of relapsed or refractory leukemias.
In the present study of 21 primary samples of acute leukemias, we demonstrated that AN-9 has antiproliferative and cytotoxic effects on leukemia cells. AN-9 arrested DNA synthesis in both T-ALL and B-precursor ALL at similar concentrations, indicating that its effects on leukemia cells were not lineage specific. More important, leukemia cells were 2- and 3-fold more sensitive than normal hematopoietic progenitors to the antiproliferative effects of AN-9 in 3H-thymidine incorporation and colony-formation assays, respectively. These findings indicate that AN-9 is less toxic to normal hematopoietic progenitors and thus has selectivity for leukemia cells. In line with these results, earlier studies in a mouse tumor model as well as a phase I clinical trial of AN-9 conducted in adults with solid tumors have shown that AN-9 has efficacy and is relatively nontoxic.19,25 Notably, in vitro data from solid tumors13,16,17 and Table 1 indicate that the IC50 of AN-9 is about 2-fold higher than that observed by us in leukemia, suggesting that leukemia cells are particularly sensitive to the cytotoxicity of AN-9. Collectively, our results indicate that AN-9 is a selective anticancer agent and may have an advantage over standard chemotherapeutic agents such as daunorubicin and doxorubicin, which are equally toxic to leukemia cells and hematopoietic progenitors in vitro.26-28 The anticancer effects of several HDAC inhibitors, including butyrate, were found to be dependent on their ability to inhibit HDACs and correlated with their capability to modulate cell-cycle and apoptosis-regulatory genes.12,23,24 A recent study reported that induction of p21 expression by butyrate was required for its effect in arresting cell growth in colon carcinoma cells.23 However, another study reported that butyrate arrested cell growth in 3T3 fibroblasts derived from p21 knockout mice, indicating that p21 was not required for the antiproliferative effects of butyrate.29 Interestingly, p21 induction by AN-9 in this study was observed only in an infant ALL sample that was the most sensitive to AN-9 cytotoxicity. The levels of p21 were not induced by AN-9 in any of the primary T-ALL or B-precursor ALL cells examined, even at AN-9 concentrations that completely inhibited DNA synthesis. Thus, it appears that AN-9 may exert its antiproliferative effects through different pathways depending on the cell type. Our results demonstrate that in addition to being an antiproliferative agent, AN-9 induces apoptosis, as observed in CEM cells. Zimra et al18 previously reported that AN-9 induced apoptosis in HL60 cells and that this was accompanied by the reduction of Bcl-2 expression. However, another study reported that butyrate activated caspase 3 and induced apoptosis in lymphoid and colorectal cancer cells that was dependent on the inhibition of HDACs but independent of changes in the levels of Bcl-2 and Bax.30 As these authors suggested, it is possible that other members of the Bcl-2/Bax family may influence butyrate-induced apoptosis. Alternatively, apoptosis could be induced through the death receptors, including CD95, tumor necrosis factor (TNF), and the receptor for the TNF-related apoptosis-inducing ligand. Although the hybrid polar HDAC inhibitor, M-carboxycinnamic acid bishydroxamide, was found to induce CD95/CD95 ligand expression, butyrate did not alter the expression of either the ligand or receptor, but did alter cell sensitivity to CD95-mediated apoptosis.31 The repression of Bcl-218 and the induction of Bax expression (A.R., unpublished observations, 1997) by AN-9 suggest that the intrinsic pathway of apoptosis that does not involve the death receptors may be the pathway responsible for AN-9-induced apoptosis. Because the precise mechanisms underlying the effects of HDAC inhibitors remain unknown, future work is aimed at further examining the pathways and key components involved in AN-9-induced growth arrest and apoptosis in ALL. Unfortunately, as with many cancers, relapses are common in ALL and are
associated with multidrug resistance. In this study, AN-9 was effective
in inhibiting the growth of HL60 myeloid and neuroblastoma clones that
harbored multiple genetic alterations32 and displayed a
multidrug-resistant phenotype.20-22 Moreover, AN-9 was
equally effective in arresting proliferation of all the primary leukemia cells tested, including a doxorubicin-resistant T-ALL, a
clinically refractory relapsed AML, and a relapsed infant ALL characterized by an 11q23 rearrangement and a very poor prognosis. Thus, our finding that AN-9 arrested the growth of these different cancer cell types indicates that AN-9 is a unique agent with potential advantage over standard chemotherapeutic agents. Similar observations have been reported using other HDAC inhibitors.10-12 For
instance, the HDAC inhibitor MS-27-275 strongly inhibited the growth of solid tumor implants in nude mice that did not respond to the standard
chemotherapeutic agent 5-fluorouracil.11 Furthermore, the
more familiar HDAC inhibitor trichostatin A was shown to inhibit proliferation and induce apoptosis in gastric and oral carcinoma cell
lines resistant to 9-cis-retinoic acid and
interferon- Thus, AN-9, an HDAC inhibitor with low toxicity and selectivity toward cancer cells, may provide a novel therapeutic strategy for cancers refractory to traditional antitumor agents. The present study provides strong evidence to warrant clinical trials in relapsed ALL using AN-9 as a single agent or in combination with standard chemotherapeutic agents.
We gratefully acknowledge the investigators from the Pediatric Oncology Group for providing T-ALL samples. We also thank Louis Bridgeman, Ruby Gribi, and Dr Sigrun Gebauer for technical assistance. We are very grateful to Dr Denis Sasaki for assistance with flow cytometry.
Submitted February 25, 2002; accepted April 30, 2002.
Prepublished online as Blood First Edition Paper, July 12, 2002; DOI 10.1182/blood-2002-02-0567.
Supported by grants from the Leukemia & Lymphoma Society 6125 (to A.L.Y.) and 6226 (to J.Y.), CA79951 (to J.Y.), The Cindy Matters Fund (to A.L.Y.), and in part by grant MO1 RR00827 from the General Clinical Research Center program. In addition, it is supported by grant 542/0 (to A.R.) from the Israel Science Foundation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Alice L.Yu, Division of Pediatric Hematology/Oncology, University of California San Diego Medical Center, 200 West Arbor Dr, San Diego, CA 92103-8447.
1. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389:349-352[CrossRef][Medline] [Order article via Infotrieve]. 2. Allfrey VG, Faulknere R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A. 1964;61:786-794. 3. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell. 1997;89:325-328[CrossRef][Medline] [Order article via Infotrieve].
4.
Marks PA, Richon VM, Rifkind RA.
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.
J Natl Cancer Inst.
2000;92:1210-1216 5. Brehm A, Nielsen SJ, Miska EA, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999;18:2449-2458[CrossRef][Medline] [Order article via Infotrieve]. 6. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000;24:300-303[CrossRef][Medline] [Order article via Infotrieve]. 7. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia. Nature. 1998;391:815-818[CrossRef][Medline] [Order article via Infotrieve]. 8. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature. 1998;391:811-814[CrossRef][Medline] [Order article via Infotrieve]. 9. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A. Distinct interactions of PML-RARalpha and PLZF-RARalpha with corepressors determine differential responses to RA in APL. Nat Genet. 1998;18:126-135[CrossRef][Medline] [Order article via Infotrieve].
10.
Warrel RP, He L-Z, Richon V, Calleja E, Pandolfi PP.
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
J Natl Cancer Inst.
1998;90:1621-1625
11.
Saito A, Yamashita T, Mariko Y, et al.
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo anti-tumor activity against human tumors.
Proc Natl Acad Sci U S A.
1999;96:4592-4597 12. Suzuki T, Yokozaki H, Kuniyasu H, et al. Effect of trichostatin A on cell growth and expression of cell cycle and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer. 2000;88:992-997[CrossRef][Medline] [Order article via Infotrieve]. 13. Nudelman A, Ruse M, Aviram A, et al. Novel anticancer prodrugs of butyric acid. J Med Chem. 1992;35:687-694[CrossRef][Medline] [Order article via Infotrieve]. 14. Aviram A, Rephaeli A, Shaklai M, et al. Effect of butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. J Cancer Res Clin Oncol. 1997;123:267-271[Medline] [Order article via Infotrieve]. 15. Zimra Y, Maron L, Shaklai M, Nudelman A, Rephaeli A. Pivaloyloxymethyl butyrate (AN-9) exhibits higher anticancer activity than butyric acid (BA): it penetrates faster than the acid and induces apoptosis in HL60 cells. Blood. 1994;84:579a. 16. Rephaeli A, Rabizadeh E, Aviram A, Shaklai M, Ruse M, Nudelman A. Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer. 1991;49:66-72[Medline] [Order article via Infotrieve]. 17. Siu LL, Von Hoff DD, Rephaeli A, et al. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest New Drugs. 1998;16:113-119[CrossRef][Medline] [Order article via Infotrieve]. 18. Zimra Y, Wasserman L, Maron L, Shaklai M, Rephaeli A, Nudelman A. Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL60 cells. J Cancer Res Clin Oncol. 1997;123:152-160[Medline] [Order article via Infotrieve]. 19. Kasukabe T, Rephaeli A, Honma Y. An anticancer derivative of butyric acid (pivaloyloxymethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukemia cells. Br J Cancer. 1997;75:850-854[Medline] [Order article via Infotrieve]. 20. Kelner MJ, McMorris TC, Montoya MA, et al. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. Cancer Chemother Pharmacol. 1997;40:65-71[CrossRef][Medline] [Order article via Infotrieve].
21.
Marsh W, Center MS.
doxorubicin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drugsensitive cells.
Cancer Res.
1987;47:5080-5086 22. LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB, Biedler JL. Multidrug resistance in human neuroblastoma cells. J Pediatr Surg. 1991;26:1107-1112[CrossRef][Medline] [Order article via Infotrieve].
23.
Archer SY, Meng S, Shei A, Hodin RA.
p21waf1 is required for butyrate-mediated growth inhibition of human colon cancer cells.
Proc Natl Acad Sci U S A.
1998;95:6791-6796
24.
Chai F, Evdokiou A, Young GP, Zalewski PD.
Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.
Carcinogenesis.
2000;21:7-14 25. Eckhardt SG, Villalona-Calero MA, Hammond L, et al. A phase I study of AN-9 (pivaloyloxymethyl butyrate, PivanexTM), a lipophilic butyric acid analog, in patients with advanced solid tumors. Proc Am Assoc Cancer Res. 1998;39:507. 26. Singer CRJ, Linch DC. Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging. Leuk Res. 1987;11:953-959[CrossRef][Medline] [Order article via Infotrieve]. 27. Spiro TE, Mattelaer M-A, Efira A, Stryckmans P. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. J Natl Cancer Inst. 1981;66:1053-1059[Medline] [Order article via Infotrieve]. 28. Linssen P, Brons P, Knops G, Wessels H, de Witte T. Plasma and cellular pharmacokinetics of m-AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU-GM, CFU-L). Eur J Haematol. 1993;50:149-154[Medline] [Order article via Infotrieve]. 29. Vaziri C, Stice L, Faller DV. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 1998;9:465-474[Abstract].
30.
Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD.
Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase). Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway.
Cancer Res.
1997;57:3697-3707 31. Bonnotte B, Favre N, Reveneau S, et al. Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. Cell Death Differ. 1998;5:480-487[CrossRef][Medline] [Order article via Infotrieve]. 32. Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma. Int J Cancer. 1999;80:145-154[CrossRef][Medline] [Order article via Infotrieve].
33.
Niitsu N, Kasukabe T, Yokoyama A, et al.
Anticancer derivative of butyric acid (pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity.
Mol Pharmacol.
2000;58:27-36
34.
Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR.
Molecular basis for the synergistic interaction of doxorubicin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
Cancer Res.
2001;61:8194-8202
35.
Zeman SM, Phillips DR, Crothers DM.
Characterization of covalent doxorubicin-DNA adducts.
Proc Natl Acad Sci U S A.
1998;95:11561-11565
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Scuto, M. Kirschbaum, C. Kowolik, L. Kretzner, A. Juhasz, P. Atadja, V. Pullarkat, R. Bhatia, S. Forman, Y. Yen, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells Blood, May 15, 2008; 111(10): 5093 - 5100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Fantin and V. M. Richon Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications Clin. Cancer Res., December 15, 2007; 13(24): 7237 - 7242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moldenhauer, R. C. Frank, J. Pinilla-Ibarz, G. Holland, P. Boccuni, D. A. Scheinberg, A. Salama, K. Seeger, M. A. S. Moore, and S. D. Nimer Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins J. Leukoc. Biol., September 1, 2004; 76(3): 623 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Pui, M. V. Relling, and J. R. Downing Acute Lymphoblastic Leukemia N. Engl. J. Med., April 8, 2004; 350(15): 1535 - 1548. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, generated as a result of a translocation in
acute promyelocytic leukemia (APL), suppressed transcription by
recruiting HDACs and thus interfering with normal cell growth and
differentiation.
indicates T-ALL; 
,
B-precursor ALL; 
, relapsed infant ALL; 
, diagnosed
infant ALL; 
, normal bone marrow. All experimental conditions were
performed in triplicate. Error bars represent standard error of the
mean for data obtained with normal bone marrow (n = 6) and primary
T-ALL (n = 16). For data obtained with infant ALL (n = 1) and for a
representative B-precursor ALL (n = 1), error bars represent standard
deviation.
,
BFU-E. Error bars represent standard error of the mean.
